… agents such as erlotinib or cetuximab. In contrast to the biomarker results of the PA.3 study,
we found a higher rate of KRAS wild-type patients within our translational study population (…

… versus chemotherapy as first-line treatment for patients with … III study), 9 a study conducted
in China comparing erlotinib and … patients, demonstrated significantly longer PFS with erlotinib …

… the current study was that by increasing the dose of erlotinib until … study of erlotinib in the
first-line setting of advanced NSCLC evaluated prospectively if increasing the dose of erlotinib …

… Compared with the efficacy of neoadjuvant PD-1 (CD274 molecule) blockade, the general
pathologic response observed with erlotinib in the current study was unimpressive (MPR, 9.7…

… The clinical benefit of erlotinib in treating epidermal growth factor receptor (EGFR) wildtype
… of erlotinib in confirmed EGFR wildtype patients in two placebo-controlled phase III trials: the …

… Although front-line phase III studies testing this concept in advanced NSCLC patients
were negative [3, 4], pharmacodynamic separation of chemotherapy, and EGFR-TKIs were …

LBA8005 Background: Second-line therapy for advanced NSCLC patients (pts) after progression
on platinum-based regimens typically employs CT or E. Improved PFS in E-treated pts …

… patients were … , this study identified a selected population of patients who achieved a median
of nearly 1 year of clinical benefit following failure of chemotherapy and gefitinib or erlotinib. …

… For patients with KRAS wild type … study design, in which the combination of abemaciclib
with best supportive care (BSC) versus erlotinib with BSC will be evaluated in pretreated patients …

… for participating and enrolling patients in this study M. Leberre: Dr. … Erlotinib is a direct and
reversible EGFR tyrosine kinase inhibitor. Combining sorafenib and erlotinib in HCC patients …